Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The brokerage business remains robust, and the profitability of emerging businesses is improving. The company has a strong platform barrier and is enhancing its brokerage framework while securing housing resources [7] - The company faces significant GTV pressure in Q4 2025 due to a noticeable decline in transaction activity in both the primary and secondary markets, which may impact brokerage revenue [7] - The company has adjusted its revenue forecasts downward for 2025-2027, with net profit estimates revised to 3.6 billion, 5.4 billion, and 6.4 billion yuan respectively [7] Financial Data and Earnings Forecast - Revenue projections for 2023 to 2027 are as follows: - 2023: 77.777 billion yuan - 2024: 93.457 billion yuan - 2025E: 94.606 billion yuan - 2026E: 94.464 billion yuan - 2027E: 100.799 billion yuan - Net profit attributable to ordinary shareholders is forecasted as: - 2023: 5.883 billion yuan - 2024: 4.065 billion yuan - 2025E: 3.585 billion yuan - 2026E: 5.361 billion yuan - 2027E: 6.371 billion yuan - The company’s earnings per share (EPS) is projected to be: - 2023: 1.63 yuan - 2024: 1.15 yuan - 2025E: 1.04 yuan - 2026E: 1.55 yuan - 2027E: 1.84 yuan [6][8]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 206.11 HKD per share [3][5][14]. Core Insights - The report highlights the strengthening of the flash purchase synergy, which is expected to enhance revenue potential. The company has adjusted its GMV and CMR growth forecasts for FY2026-2028, projecting revenues of 10,165/11,481/12,652 billion CNY and net profits of 1,258/1,744/2,013 billion CNY respectively [3][14]. - The Double Eleven shopping festival has seen an extension in its promotional period and simplification of its promotional strategies, which has improved consumer experience and increased order conversion rates. The synergy between the flash purchase and the main site has been enhanced, contributing significantly to order volume [9][12]. - The report notes that new user orders from flash purchases during the Double Eleven period exceeded 100 million, indicating that flash purchase synergy has become a crucial growth driver for the main site [9][12]. Financial Projections - The company’s projected revenues for FY2026-2028 are 10,165 billion CNY, 11,481 billion CNY, and 12,652 billion CNY, with corresponding net profits of 1,258 billion CNY, 1,744 billion CNY, and 2,013 billion CNY [3][11][14]. - The report provides detailed quarterly financial forecasts, indicating a slight revenue growth in FY2026 compared to FY2025, with a projected revenue of 1,016,593 million CNY [15]. Market Performance - The report includes a performance analysis, showing a relative performance of -4.32% over one month and a significant increase of 70.19% over the past year [6]. Valuation - The report calculates the company's market value at 35,846 billion CNY based on a segment valuation approach, leading to a per-share value of 206.11 HKD [3][17].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported total revenue of 231 billion yuan for Q3 2025, a year-on-year increase of 2.1%, while adjusted net profit was 12.86 billion yuan, down 12.8% year-on-year [7] - The total transaction volume remained stable at 736.7 billion yuan, but the decline in profit margins led to a decrease in net profit, with gross margin dropping to 21.4% from 22.7% in the same period last year [7] - The home decoration and rental services segments achieved profitability at the city level for two consecutive quarters, with home decoration revenue of 4.3 billion yuan and a profit margin of 32.0%, up 0.8 percentage points year-on-year [7] - The company has increased shareholder returns, spending approximately 280 million USD on share buybacks in Q3, a 38.3% increase year-on-year, marking a two-year high [7] - The company is actively expanding its diversified businesses, including home decoration and rental services, despite facing short-term performance pressure due to a sluggish real estate market [7] Financial Performance Summary - Revenue projections for the company are as follows: 77.777 billion yuan in 2023, 93.457 billion yuan in 2024, 97.986 billion yuan in 2025, 106.438 billion yuan in 2026, and 110.849 billion yuan in 2027, with a revenue growth rate of 28.20% in 2023 and declining to 4.14% by 2027 [6] - Adjusted net profit is forecasted to be 9.798 billion yuan in 2023, decreasing to 5.790 billion yuan in 2025, before recovering to 8.308 billion yuan in 2027 [6] - The company's price-to-earnings (PE) ratio is projected to be 14.08 in 2023, increasing to 23.82 in 2025, and then decreasing to 16.60 by 2027 [6]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of $35 for US shares and HK$27 for Hong Kong shares, indicating a potential upside of 51% and 56% respectively [5][11]. Core Insights - The company's 3Q25 performance was below expectations, with total revenue of $116 million, representing a 13.5% year-over-year increase but significantly lower than forecasts. The net loss narrowed to $35.96 million, slightly above expectations [2][3]. - The report emphasizes the importance of the core pipeline asset Zoci, which is expected to have multiple data readouts in 1H26 that could positively impact the stock price [1][4]. - The revenue guidance for 2025 has been revised down from $560-590 million to at least $460 million, reflecting a 18%-22% reduction in expected annual revenue [4][11]. Financial Performance Summary - 3Q25 total revenue was $116 million, with product revenue of $115 million, both lower than expected. The product gross margin was 59.5%, continuing a downward trend [2][3]. - R&D expenses were reduced by 27.4% year-over-year to $47.93 million, indicating effective cost control [2]. - The company expects to submit applications for key products by the end of 2025, with global Phase 1 clinical trials for Zoci anticipated to start in 1H26 [11][12]. Pipeline and Future Prospects - The report highlights several upcoming catalysts for Zoci, including updates on intracranial efficacy data and potential registration trials in 2026 [4][11]. - Other pipeline assets are also expected to yield important data, including ZL-1503 and ZL-6201, with readouts anticipated in 2026 [4][11]. Market Expectations - The current market capitalization is approximately $2.56 billion, with a recent average trading volume of $22 million [5]. - The stock has a 52-week price range of $21.6 to $44.3, indicating significant volatility [5].

Investment Rating - The report maintains an "Outperform" rating for BeiGene with a target price of HKD 213.10, reflecting a positive outlook on the company's performance [2][17]. Core Insights - In Q3 2025, BeiGene reported revenue of USD 1.41 billion, representing a year-on-year increase of 41% and a quarter-on-quarter increase of 7.7%. The gross profit margin was 86.1%, up by 3.1 percentage points year-on-year. The company achieved a net profit of USD 120 million for the quarter [3][13]. - Management has raised the full-year 2025 revenue guidance to USD 5.1–5.3 billion, slightly lowering the operating expenses guidance to USD 4.1–4.3 billion [3][13]. Revenue and Profit Forecasts - Revenue projections for FY25, FY26, and FY27 have been increased to USD 5.3 billion, USD 6.4 billion, and USD 7.1 billion, respectively, indicating a three-year compound annual growth rate (CAGR) of 23% [16][17]. - Net profit attributable to shareholders is forecasted to be USD 360 million, USD 660 million, and USD 1.05 billion for FY25, FY26, and FY27, respectively [16][17]. Product Performance - Zanubrutinib (BRUKINSA) generated global revenue of USD 1.04 billion in Q3 2025, with significant contributions from the U.S. (USD 740 million), Europe (USD 160 million), and China (USD 90 million). The global revenue for Zanubrutinib is expected to exceed USD 3.9 billion in 2025 [4][15]. - Tislelizumab (PD-1) reported global revenue of USD 190 million, reflecting a year-on-year increase of 16.7% [15]. Clinical Development Focus - The report highlights the importance of clinical progress in the hematologic oncology portfolio, particularly the BCL-2 inhibitor and BTK CDAC. Management plans to submit a new drug application for the R/R MCL indication and initiate a head-to-head trial in treatment-naïve chronic lymphocytic leukemia patients [14][15]. - In the solid tumor space, the focus is on the CDK4 inhibitor and B7-H4 ADC, with ongoing clinical trials and dose optimization efforts [15][16]. Valuation Methodology - The company is valued using a Discounted Cash Flow (DCF) model, with a WACC of 9% and a perpetual growth rate of 4%. The target price of HKD 213.10 reflects the company's growth potential and market position [17].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report emphasizes the value of the ATTC platform and the continuous development of potential pipelines [5][7] - The company is advancing innovative treatments for cancer and immune diseases, showcasing its proprietary ATTC platform and the latest progress in late-stage pipeline candidates [7] Financial Performance and Forecast - The company’s projected revenues for 2025, 2026, and 2027 are $567 million, $676 million, and $816 million respectively, with growth rates of -10.0%, 19.2%, and 20.7% [6][8] - The expected net profit for 2025, 2026, and 2027 is $426 million, $94 million, and $138 million respectively, with growth rates of 1029.3%, -78.0%, and 46.7% [6][8] - The report anticipates a reasonable equity value of HKD 26.9 billion based on DCF calculations, assuming a perpetual growth rate of 2% and a WACC of 9.43% [7] Pipeline Development - The ATTC platform is a novel cancer precision therapy development platform that combines monoclonal antibodies with proprietary targeted small molecule inhibitors, aiming for superior anti-tumor activity and safety [7] - The first potential pipeline candidate from this platform is HMPL-A251, which has shown promising anti-tumor efficacy and tolerability in preclinical studies, with plans to enter clinical development by the end of 2025 [7] - Ongoing projects include: 1. FRUSICA-2 study for fruquintinib combined with sintilimab in renal cell carcinoma [7] 2. SANOVO study for savolitinib in non-small cell lung cancer [7] 3. Ongoing studies for surufatinib in pancreatic cancer [7] 4. HMPL-453 for intrahepatic cholangiocarcinoma, with plans for a new drug application in mid-2026 [7]

Investment Rating - The report assigns a "Buy" rating for the company with a target price of HKD 105, representing a potential upside of 32.16% from the current price of HKD 79.45 [4]. Core Insights - The company's revenue is projected to recover significantly, with a forecasted increase of 40.5% in 2025 and 22.5% in 2026, following a decline in the previous years [3]. - Gross margin is expected to improve, reaching 20.6% by 2027, up from 10.2% in 2023 [3]. - The company is benefiting from a strong demand for its products, particularly in the embedded non-volatile memory and power device segments, with notable growth rates of 20.4% and 3.5% year-on-year, respectively [5]. - The production capacity utilization rate remains high at 109.5%, indicating efficient operations and potential for further revenue growth [5]. - The report anticipates continued positive performance in the semiconductor industry, positioning the company as a key beneficiary of domestic substitution trends [5]. Financial Summary - Total revenue for the fiscal year ending December 31, 2022, was USD 2,286.1 million, with a projected increase to USD 3,459.3 million by 2025 [3]. - Shareholder net profit is expected to rise from USD 80.3 million in 2025 to USD 322.7 million by 2027, reflecting a strong recovery trajectory [3]. - The earnings per share (EPS) is forecasted to increase from USD 0.05 in 2025 to USD 0.18 in 2027 [3]. - The company’s market capitalization is currently HKD 105.49 billion, with a price-to-earnings (P/E) ratio of 218.0 for 2025, which is expected to decrease to 57.0 by 2027 [4][6]. Operational Highlights - The company has optimized its product mix, with all process platforms showing positive revenue growth [5]. - The average selling price (ASP) for wafer foundry services is projected to reach approximately USD 500 by 2027, indicating a robust pricing strategy [5]. - The company is also expanding its production capabilities, with the FAB5 facility expected to contribute an additional USD 600-700 million in revenue once operational [5].

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Views - The company has experienced a rebound in sales volume for the first time this year, with a quarterly performance showing signs of recovery [2][6]. - The company's installed capacity has expanded, leading to a 9.2% year-on-year increase in controlled power generation, reaching 2.518 billion kWh in the third quarter [6]. - Despite a 3.03% year-on-year decrease in revenue to 3.541 billion yuan, the net profit attributable to shareholders surged by 122.97% to 147 million yuan due to cost control and increased investment income [2][6]. Summary by Sections Revenue and Sales Volume - The company reported a total sales volume of 944 million cubic meters in the third quarter, marking a 0.94% year-on-year increase, reversing the downward trend observed since the end of last year [6]. - The wholesale gas volume increased by 27.66% to 334 million cubic meters, while retail gas volume decreased by 21.99% to 308 million cubic meters [6]. Cost Management and Profitability - The company effectively controlled costs, resulting in a gross profit of 425 million yuan, a decline of 7.77% year-on-year, while financial expenses decreased by 15.70% to 255 million yuan [6]. - Investment income rose by 130.13% to 57 million yuan, contributing to the significant increase in net profit [6]. Future Outlook - The La Niña phenomenon is expected to lead to a colder winter, which may increase heating demand and positively impact gas sales and wind power generation [6]. - The company has adjusted its earnings forecast for 2025-2027, expecting profits of 2.038 billion yuan, 2.248 billion yuan, and 2.480 billion yuan, with corresponding EPS of 0.48 yuan, 0.53 yuan, and 0.59 yuan [6].

Investment Rating - The report assigns a "Buy" rating for China Taiping (00966.HK) with a target price of HKD 22.6 [1][6][9] Core Views - China Taiping is positioned as a leader in the transformation towards participating insurance, with a strong potential for valuation recovery. The company is actively pushing for this transformation, which is expected to reduce rigid costs from new policies and alleviate the pressure from declining interest rates [8][9][10] Financial Performance - The projected insurance service revenue for 2024 is HKD 22,024 million, with a year-on-year growth of 18.8%. The net profit attributable to shareholders is expected to reach HKD 8,432 million, reflecting a significant year-on-year increase of 36.2% [2][3] - The earnings per share (EPS) for 2024 is forecasted at HKD 2.35, with a price-to-earnings (P/E) ratio of 7.8 [2][3] Business Segments Life Insurance - China Taiping's life insurance segment is a key driver, contributing approximately 80% of the net profit. The new business value (NBV) has started to recover in 2023, with a year-on-year increase of 23% to HKD 6.8 billion in 2025H1 [6][32] - The company has a robust channel structure, primarily through individual agents, with a significant shift towards participating insurance, which accounted for 29% of the new business in 2025H1 [32][52] Property and Casualty Insurance - The domestic property and casualty insurance business is gradually improving, with a combined ratio (COR) of 95.5% in 2025H1, indicating a year-on-year improvement [59][60] - The overseas property and casualty insurance segment, primarily in Hong Kong and Macau, has shown slower growth, contributing 14% to the overall property and casualty business [67] Asset Management - The asset management segment has seen steady growth, with total managed assets exceeding HKD 2.65 trillion as of 2025H1. The investment performance has been influenced by interest rates, with a focus on equity allocations expected to yield strong beta opportunities [6][9][10] Valuation and Estimates - The report utilizes the Present Value of Embedded Value (PEV) method for valuation, predicting an embedded value per share (EVPS) of HKD 56, 64.6, and 74.1 for 2025, 2026, and 2027 respectively. The current dynamic PEV is estimated at 0.33x for 2025 and 0.28x for 2026, with a target PEV of 0.35x for 2026 [9][10]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is expected to accelerate growth in its K12 business in FY2026Q2, with a projected revenue increase of 9% to 12% year-over-year [4] - The company plans to return $490 million to shareholders through dividends and share buybacks, with a dividend of $0.12 per share [3] - Despite a slowdown in overseas business and revenue growth, the company achieved a revenue of $1.52 billion in FY2026Q1, exceeding previous guidance by 1% [2][4] Financial Performance - For FY2026Q1, the company reported a Non-GAAP operating profit of $340 million, a year-over-year increase of 11.8%, with an operating profit margin of 22% [2] - The company expects FY2026-2028 revenues of $5.36 billion, $5.98 billion, and $6.50 billion, respectively, with corresponding net profits of $461 million, $542 million, and $619 million [4][8] - The company has cash and cash equivalents of $1.28 billion, with short-term investments totaling $2.18 billion as of FY2026Q1 [3] Market Performance - The company's stock has outperformed the Hang Seng Index by 2.6% over the past month, while the Hang Seng Index has seen a decline of 2.7% [5] - The current stock price is HKD 41.86, with a market capitalization of approximately HKD 66.62 billion [5] Future Outlook - The company anticipates improved profit margins in FY2026Q2, driven by enhanced K12 teaching quality and increased student retention rates [4] - The report indicates a cautious outlook on revenue and profit forecasts due to the impact of international economic conditions on traditional study abroad and new cultural tourism businesses [4]